stockrowProtalix BioTherapeutics, Inc. (PLX) vs Sol-Gel Technologies Ltd. (SLGL)
- Protalix BioTherapeutics, Inc. PLX 2.54 +1.20%
- Sol-Gel Technologies Ltd. SLGL 61.01 −3.17%
Protalix BioTherapeutics, Inc. and Sol-Gel Technologies Ltd. are both Biotechnology companies. Protalix BioTherapeutics, Inc. and Sol-Gel Technologies Ltd. are of similar size ($204.7M and $199.8M). Sol-Gel Technologies Ltd. has negative trailing earnings, so its P/E is not meaningful; Protalix BioTherapeutics, Inc. trades at 10.6×. Protalix BioTherapeutics, Inc. grew revenue faster over the last twelve months: 30.1% against −92.5%. Protalix BioTherapeutics, Inc. has the higher net margin (23.5% vs −910.1%) and the higher return on invested capital (48.5% vs −6,630.2%). Across the 17 metrics below, Protalix BioTherapeutics, Inc. leads on 12 and Sol-Gel Technologies Ltd. on 5.
Valuation
Profitability
| Metric | PLX | SLGL | Biotechnology median |
|---|---|---|---|
| Gross margin | 69.20% | 100.00% | 68.51% |
| Operating margin | 28.89% | (986.96%) | 0.00% |
| Net margin | 23.50% | (910.14%) | 0.00% |
| Free cash flow margin | 9.51% | (1,185.18%) | 0.00% |
| Return on equity | 31.23% | (40.85%) | (51.96%) |
| Return on assets | 20.07% | (35.11%) | (46.06%) |
| Return on invested capital | 48.48% | (6,630.24%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack